ArticleCureus2026
Effective Management of Recurrent Conjunctival Intraepithelial Neoplasia Using Topical Mitomycin C 0.02.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conjunctival intraepithelial neoplasia (CIN) is a premalignant lesion within the ocular surface squamous neoplasia (OSSN) spectrum that may recur after treatment and can progress to invasive squamous cell carcinoma (SCC) if left untreated. Management options include surgical excision, topical chemotherapeutic agents, immunotherapy, and radiotherapy in selected cases. A 64-year-old Egyptian man presented with a recurrent conjunctival mass in the right eye associated with irritation and discomfort. He had undergone surgical excision of a similar lesion at the same site 10 years earlier, with histopathological confirmation of CIN. Examination revealed a 6 × 7 mm raised, vascularized, irregular gelatinous lesion on the nasal conjunctiva, extending from the caruncle to the limbus with approximately 2 mm of nasal corneal epithelial involvement. The recurrent lesion was treated without current repeat surgical excision using topical mitomycin C (MMC) 0.02% in a cyclic regimen. Marked clinical regression was observed after four weeks. A second course was administered for a small residual lesion, resulting in complete clinical regression with mild localized scarring. The treatment was well tolerated, with only mild transient ocular discomfort, conjunctival injection, and tearing. The patient was followed for more than one year after treatment completion, with no documented clinical recurrence. This case suggests that topical MMC 0.02% may be an effective conservative treatment option for selected patients with recurrent CIN. Longer follow-up and larger studies are needed to confirm sustained efficacy, recurrence risk, and long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.